In a similar fashion, RMC-6236 is a non-selective RAS(ON) inhibitor that has demonstrated tumor shrinking across various KRAS genotypes, including G12D, G12V, and G12R mutations [149]. The gene discussed is KRAS; the disease is neoplasm.